Procter & Gamble Wins Generic-Drug Suit Against Teva
February 28, 2008 — GPCI
February 28, 2008 - Procter & Gamble Co. won a patent infringement lawsuit against Teva Pharmaceuticals USA Inc. over a generic version of P&G's osteoporosis drug Actonel that the Israel-based Teva wanted to market in the US.
P&G filed the lawsuit against Teva to enforce P&G's patent for risedronate, the active ingredient in Actonel. Teva had claimed P&G's Actonel patent was not valid due to the obviousness of the invention.
Just updated to include the latest changes in patent law and intellectual property best practices, the Second Edition of Essentials of Intellectual Property is the definitive primer on patents, trademarks, copyrights and trade secrets. Full of valuable tips, techniques, real-world examples and exhibits, this handy and concise book provides inventors, business executives and others involved in intellectual property with an understanding of the basics.
Buy Second Edition - Essentials of Intellectual Property
Written by acknowledged experts in the field, Essentials of Intellectual Property Licensing provides managers with a clear, concise overview of IP licensing.
In practical, down-to- earth language it clearly explains licensing strategies; deal making; royalties and royalty rates; patent, trademark and copyright licenses; and basic contract law.
RSS Subscribe
Oblviousness No Excuse on Patent Infringement
May 03, 2009 — AnonymousI think P & G should have won as they did. Oblviousness of an invention is no excuse. The same goes with your driver's license and many other important issues. A person and/or company needs to be informed of important issues such as patents and patent infringement.